|Ketone bodies: acetone, acetoacetic acid, and beta-hydroxybutyric acid|
Ketosis is a metabolic state characterized by elevated levels of ketone bodies in the blood or urine. Physiologic ketosis is a normal response to low glucose availability, such as low-carbohydrate diets or fasting, that provides an additional energy source for the brain in the form of ketones. In physiologic ketosis, ketones in the blood are elevated above baseline levels, but the body's acid-base homeostasis is maintained. This contrasts with ketoacidosis, an uncontrolled production of ketones that occurs in pathologic states and causes a metabolic acidosis, which is a medical emergency. Ketoacidosis is most commonly the result of complete insulin deficiency in type 1 diabetes or late-stage type 2 diabetes. Ketone levels can be measured in blood, urine or breath and are generally between 0.5 and 3.0 millimolar (mM) in physiologic ketosis, while ketoacidosis may cause blood concentrations greater than 10 mM.
Trace levels of ketones are always present in the blood and increase when blood glucose reserves are low and the liver shifts from primarily metabolizing carbohydrates to metabolizing fatty acids. This occurs during states of increased fatty acid oxidation such as fasting, starvation, carbohydrate restriction, or prolonged exercise. When the liver rapidly metabolizes fatty acids into acetyl-CoA, some acetyl-CoA molecules can then be converted into ketone bodies: acetoacetate, beta-hydroxybutyrate, and acetone. These ketone bodies can function as an energy source as well as signalling molecules. The liver itself cannot utilize these molecules for energy, so the ketone bodies are released into the blood for use by peripheral tissues including the brain.
When ketosis is induced by carbohydrate restriction, it is sometimes referred to as nutritional ketosis. A low-carbohydrate, moderate protein diet that can lead to ketosis is called a ketogenic diet. Ketosis is well-established as a treatment for epilepsy and is also effective in treating type 2 diabetes. The possible effect on a range of neurological diseases, metabolic syndrome, cancer, and other conditions is currently under investigation.
Physiologic ketosis is a normal physiologic state characterized by elevated serum ketones and normal blood glucose and blood pH. Increasing production of ketone bodies is a response to low glucose availability that creates an alternate energy source for the brain. Physiologic ketosis can result from any state that increases fatty acid oxidation including fasting, prolonged exercise, or very low-carbohydrate diets such as the ketogenic diet. When physiologic ketosis is induced by carbohydrate restriction, it is sometimes referred to as nutritional ketosis. Ketone levels generally remain below 3 mM.
Ketoacidosis is a pathological state of uncontrolled production of ketones that results in a metabolic acidosis. Ketoacidosis is most commonly caused by a deficiency of insulin in type 1 diabetes or late stage type 2 diabetes but can also be the result of chronic heavy alcohol use, salicylate poisoning, or isopropyl alcohol ingestion. Ketoacidosis causes significant metabolic derangements and is a life-threatening medical emergency. Ketoacidosis is distinct from physiologic ketosis as it requires failure of the normal regulation of ketone body production.
Elevated blood ketone levels are most often caused by accelerated ketone production but may also be caused by consumption of exogenous ketones or precursors.
When glycogen and blood glucose reserves are low, a metabolic shift occurs in order to save glucose for the brain which is unable to use fatty acids for energy. This shift involves increasing fatty acid oxidation and production of ketones in the liver as an alternate energy source for the brain as well as the skeletal muscles, heart, and kidney. Low levels of ketones are always present in the blood and increase under circumstances of low glucose availability. For example, after an overnight fast, 2-6% of energy comes from ketones and this increases to 30-40% after a 3-day fast.
The amount of carbohydrate restriction required to induce a state of ketosis is variable and depends on activity level, insulin sensitivity, genetics, age and other factors, but ketosis will usually occur when consuming less than 50 grams of carbohydrates per day for at least three days.
Neonates, pregnant women and lactating women are populations that develop physiologic ketosis especially rapidly in response to energetic challenges such as fasting or illness. This can progress to ketoacidosis in the setting of illness, although it occurs rarely. Propensity for ketone production in neonates is caused by their high-fat breast milk diet, disproportionately large central nervous system and limited liver glycogen.
The precursors of ketone bodies include fatty acids from adipose tissue or the diet and ketogenic amino acids. The formation of ketone bodies occurs via ketogenesis in the mitochondrial matrix of liver cells.
Fatty acids can be released from adipose tissue by adipokine signaling of high glucagon and epinephrine levels and low insulin levels. High glucagon and low insulin correspond to times of low glucose availability such as fasting. Fatty acids bound to coenzyme A allow penetration into mitochondria. Once inside the mitochondrion, the bound fatty acids are used as fuel in cells predominantly through beta oxidation, which cleaves two carbons from the acyl-CoA molecule in every cycle to form acetyl-CoA. Acetyl-CoA enters the citric acid cycle, where it undergoes an aldol condensation with oxaloacetate to form citric acid; citric acid then enters the tricarboxylic acid cycle (TCA), which harvests a very high energy yield per carbon in the original fatty acid.
Acetyl-CoA can be metabolized through the TCA cycle in any cell, but it can also undergo ketogenesis in the mitochondria of liver cells. When glucose availability is low, oxaloacetate is diverted away from the TCA cycle and is instead used to produce glucose via gluconeogenesis. This utilization of oxaloacetate in gluconeogenesis can make it unavailable to condense with acetyl-CoA, preventing entrance into the TCA cycle. In this scenario, energy can be harvested from acetyl-CoA through ketone production.
In ketogenesis, two acetyl-CoA molecules condense to form acetoacetyl-CoA via thiolase. Acetoacetyl-CoA briefly combines with another acetyl-CoA via HMG-CoA synthase to form hydroxy-β-methylglutaryl-CoA. Hydroxy-β-methylglutaryl-CoA form the ketone body acetoacetate via HMG-CoA lyase. Acetoacetate can then reversibly convert to another ketone body—D-β-hydroxybutyrate—via D-β-hydroxybutyrate dehydrogenase. Alternatively, acetoacetate can spontaneously degrade to a third ketone body (acetone) and carbon dioxide, which generates much greater concentrations of acetoacetate and D-β-hydroxybutyrate. The resulting ketone bodies cannot be used for energy by the liver so are exported from the liver to supply energy to the brain and peripheral tissues.
Ketone levels can be measured by testing urine, blood or breath. There are limitations in directly comparing these methods as they measure different ketone bodies.
Urine testing is the most common method of testing for ketones. Urine test strips utilize a nitroprusside reaction with acetoacetate to give a semi-quantitative measure based on color change of the strip. Although beta-hydroxybutyrate is the predominant circulating ketone, urine test strips only measure acetoacetate. Urinary ketones often correlate poorly with serum levels because of variability in excretion of ketones by the kidney, influence of hydration status, and renal function.
This section may primarily relate to a different subject, or place undue weight on a particular aspect rather than the subject as a whole. (May 2020)
Type 2 diabetes
Ketosis induced by a very low-carbohydrate diet is supported as an effective treatment for type 2 diabetes and can improve blood glucose metrics even with reduction or discontinuation of antidiabetic medications. Ketosis can be an effective treatment for this population by reducing dietary glucose load, increasing insulin sensitivity as well as reducing hepatic glucose output. This results in reduction in fasting glucose and insulin and hemoglobin A1c as well as reduced need for exogenous insulin.
Obesity and metabolic syndrome
Ketosis can improve markers of metabolic syndrome through reduction in serum triglycerides, elevation in high-density lipoprotein (HDL) as well as increased size and volume of low-density lipoprotein (LDL) particles. These changes are consistent with an improved lipid profile despite potential increases in total cholesterol level.
Ketosis is being investigated for a growing number of conditions, however clinical recommendations for these conditions cannot yet be made based on the current level of evidence.
Neurological diseases: In addition to its use for epilepsy, ketosis is being investigated in other neurological diseases because of its proposed neuroprotective effects including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), autism, migraine headache, neurotrauma, pain, Parkinson's disease, and sleep disorders.
Cancer: Preclinical studies have indicated ketosis may have anti-tumor effects, however clinical trials have been limited by small sample sizes and have not shown conclusive benefit.
Glycogenosis Ketosis has been reported to alleviate symptoms related to Glycogenosis as in some Glycogen storage diseases. GSDs which are characterised by the inability of tissues to utilise glycogen stores, such as McArdle disease, may be managed with a Ketogenic Diet by ensuring that tissues are using ketone bodies for energy and not the impaired pathways of glycogen utilisation for glycolysis.
Other conditions: There is emerging evidence for the use of ketosis in other conditions such as type 1 diabetes, non-alcoholic fatty liver disease, acne, polycystic kidney disease and polycystic ovary syndrome, however evidence quality is limited by small sample sizes. 
The safety of ketosis from low-carbohydrate diets is often called into question by clinicians, researchers and the media. A common safety concern stems from the misunderstanding of the difference between physiologic ketosis and pathologic ketoacidosis. There is also continued debate whether chronic ketosis is a healthy state or a stressor to be avoided. Some argue that humans evolved to avoid ketosis and should not be in ketosis long-term. The counter-argument is that there is no physiologic requirement for dietary carbohydrate as adequate energy can be made via gluconeogenesis and ketogenesis indefinitely. Alternatively, the switching between a ketotic and fed state has been proposed to have beneficial effects on metabolic and neurologic health. The effects of sustaining ketosis for up to two years are known from studies of people following a strict ketogenic diet for epilepsy or type 2 diabetes, and these including short-term adverse effects leading to potential long-term ones. However, literature on longer term effects or intermittent ketosis is lacking.
Some medications require attention when in a state of ketosis, especially several classes of diabetes medication. SGLT2 inhibitor medications have been associated with cases of euglycemic ketoacidosis- a rare state of high ketones causing a metabolic acidosis with normal blood glucose levels. This usually occurs with missed insulin doses, illness, dehydration or adherence to a low-carbohydrate diet while taking the medication. Additionally, medications used to directly lower blood glucose including insulin and sulfonylureas may cause hypoglycemia if they are not titrated prior to starting a diet that results in ketosis.
The most common side effects of ketosis include headache, fatigue, dizziness, insomnia, difficulty in exercise tolerance, constipation, and nausea, especially in the first days and weeks after starting a ketogenic diet. Breath may develop a sweet, fruity flavor via production of acetone that is exhaled because of its high volatility.
Most adverse effects of long-term ketosis reported are in children because of its longstanding acceptance as a treatment for pediatric epilepsy. These include compromised bone health, stunted growth, hyperlipidemia, and kidney stones.
Ketosis induced by a ketogenic diet should not be pursued by people with pancreatitis because of the high dietary fat content. Ketosis is also contraindicated in pyruvate carboxylase deficiency, porphyria, and other rare genetic disorders of fat metabolism.
In dairy cattle, ketosis commonly occurs during the first weeks after giving birth to a calf and is sometimes referred to as acetonemia. This is the result of an energy deficit when intake is inadequate to compensate for the increased metabolic demand of lactating. The elevated β-hydroxybutyrate concentrations can depress gluconeogenesis, feed intake and the immune system as well as have an impact on milk composition. Point of care diagnostic tests can be useful to screen for ketosis in cattle.
In sheep, ketosis, evidenced by hyperketonemia with beta-hydroxybutyrate in blood over 0.7 mmol/L, is referred to as pregnancy toxemia. This may develop in late pregnancy in ewes bearing multiple fetuses and is associated with the considerable metabolic demands of the pregnancy. In ruminants, because most glucose in the digestive tract is metabolized by rumen organisms, glucose must be supplied by gluconeogenesis. Pregnancy toxemia is most likely to occur in late pregnancy due to metabolic demand from rapid fetal growth and may be triggered by insufficient feed energy intake due to weather conditions, stress or other causes. Prompt recovery may occur with natural parturition, Caesarean section or induced abortion. Prevention through appropriate feeding and other management is more effective than treatment of advanced stages of pregnancy toxemia.
- Healthline, Noreen Iftikhar, MD
- Laffel, Lori (November 1999). "Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes". Diabetes/Metabolism Research and Reviews. 15 (6): 412–426. doi:10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8. PMID 10634967.
- Ward C (2015). "Ketone Body Metabolism". Diapedia. doi:10.14496/dia.51040851169.29. Archived from the original on 2018-11-11. Retrieved 30 September 2019.
- Mattson MP, Moehl K, Ghena N, Schmaedick M, Cheng A (2018). "Intermittent metabolic switching, neuroplasticity and brain health". Nature Reviews. Neuroscience. 19 (2): 63–80. doi:10.1038/nrn.2017.156. PMC 5913738. PMID 29321682.
- Westman, Eric C.; Tondt, Justin; Maguire, Emily; Yancy, William S. (15 September 2018). "Implementing a low-carbohydrate, ketogenic diet to manage type 2 diabetes mellitus". Expert Review of Endocrinology & Metabolism. 13 (5): 263–272. doi:10.1080/17446651.2018.1523713. PMID 30289048.
- Ketogenic diet improves metabolic syndrome in multiple ways, diabetes.co.uk, Dec. 2017
- Gershuni, Victoria M.; Yan, Stephanie L.; Medici, Valentina (20 August 2018). "Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome". Current Nutrition Reports. 7 (3): 97–106. doi:10.1007/s13668-018-0235-0. PMC 6472268. PMID 30128963.
- Krebs, H.A. (January 1966). "The regulation of the release of ketone bodies by the liver". Advances in Enzyme Regulation. 4: 339–353. doi:10.1016/0065-2571(66)90027-6. PMID 4865971.
- Cahill GF (2006). "Fuel metabolism in starvation". Annual Review of Nutrition. 26: 1–22. doi:10.1146/annurev.nutr.26.061505.111258. PMID 16848698.
- Paoli A, Rubini A, Volek JS, Grimaldi KA (2013). "Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets". European Journal of Clinical Nutrition. 67 (8): 789–96. doi:10.1038/ejcn.2013.116. PMC 3826507. PMID 23801097.
- Veech RL (2004). "The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism". Prostaglandins, Leukotrienes, and Essential Fatty Acids. 70 (3): 309–19. doi:10.1016/j.plefa.2003.09.007. PMID 14769489.
- Fukao T, Mitchell G, Sass JO, Hori T, Orii K, Aoyama Y (2014). "Ketone body metabolism and its defects". Journal of Inherited Metabolic Disease. 37 (4): 541–51. doi:10.1007/s10545-014-9704-9. PMID 24706027.
- Coelho M, Oliveira T, Fernandes R (2013). "Biochemistry of adipose tissue: an endocrine organ". Archives of Medical Science. 9 (2): 191–200. doi:10.5114/aoms.2013.33181. PMC 3648822. PMID 23671428.
- Kohlmeier, Martin (2015-05-22). Nutrient metabolism : structures, functions, and genes. ISBN 9780123877840. OCLC 913852019.
- Owen, Oliver E. (July 2005). "Ketone bodies as a fuel for the brain during starvation". Biochemistry and Molecular Biology Education. 33 (4): 246–251. doi:10.1002/bmb.2005.49403304246.
- Stryer L (1995). Biochemistry (Fourth ed.). New York: W.H. Freeman and Company. pp. 510–515, 581–613, 775–778. ISBN 0-7167-2009-4.
- Hartman AL, Vining EP (2007). "Clinical aspects of the ketogenic diet". Epilepsia. 48 (1): 31–42. doi:10.1111/j.1528-1167.2007.00914.x. PMID 17241206.
- Gano LB, Patel M, Rho JM (2014). "Ketogenic diets, mitochondria, and neurological diseases". Journal of Lipid Research. 55 (11): 2211–28. doi:10.1194/jlr.R048975. PMC 4617125. PMID 24847102.
- Gershuni VM, Yan SL, Medici V (2018). "Nutritional Ketosis for Weight Management and Reversal of Metabolic Syndrome". Current Nutrition Reports. 7 (3): 97–106. doi:10.1007/s13668-018-0235-0. PMC 6472268. PMID 30128963.
- Maalouf M, Rho JM, Mattson MP (2009). "The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies". Brain Research Reviews. 59 (2): 293–315. doi:10.1016/j.brainresrev.2008.09.002. PMC 2649682. PMID 18845187.
- Weber DD, Aminazdeh-Gohari S, Kofler B (2018). "Ketogenic diet in cancer therapy". Aging. 10 (2): 164–165. doi:10.18632/aging.101382. PMC 5842847. PMID 29443693.
- Vorgerd, M; Zange, J (July 2007). "Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle". Acta Myologica: Myopathies and Cardiomyopathies. 26 (1): 61–63. PMC 2949316. PMID 17915573.
- "Is the keto diet safe? USC experts have some serious concerns". USC News. 2019-02-19. Retrieved 2019-10-03.
- "7 Dangers of Going Keto". Health.com. Retrieved 2019-10-03.
- Plaskett, L. G. (2003). "On the Essentiality of Dietary Carbohydrate". Journal of Nutritional & Environmental Medicine. 13 (3): 161–168. doi:10.1080/13590840310001619405.
- Manninen AH (2004). "Metabolic effects of the very-low-carbohydrate diets: misunderstood "villains" of human metabolism". Journal of the International Society of Sports Nutrition. 1 (2): 7–11. doi:10.1186/1550-2783-1-2-7. PMC 2129159. PMID 18500949.
- Masood W, Uppaluri KR (2019). "Ketogenic Diet". StatPearls. StatPearls Publishing. PMID 29763005. Retrieved 2019-10-03.
- Goldenberg RM, Berard LD, Cheng AY, Gilbert JD, Verma S, Woo VC, Yale JF (2016). "SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis". Clinical Therapeutics. 38 (12): 2654–2664.e1. doi:10.1016/j.clinthera.2016.11.002. PMID 28003053.
- Kossoff EH, Zupec-Kania BA, Rho JM (2009). "Ketogenic diets: an update for child neurologists". Journal of Child Neurology. 24 (8): 979–88. doi:10.1177/0883073809337162. PMID 19535814.
- Kossoff EH, Zupec-Kania BA, Amark PE, Ballaban-Gil KR, Christina Bergqvist AG, Blackford R, et al. (2009). "Optimal clinical management of children receiving the ketogenic diet: recommendations of the International Ketogenic Diet Study Group". Epilepsia. 50 (2): 304–317. doi:10.1111/j.1528-1167.2008.01765.x. PMID 18823325.
- Gross JJ, Bruckmaier RM (2019). "Review: Metabolic challenges in lactating dairy cows and their assessment via established and novel indicators in milk". Animal. 13 (S1): s75–s81. doi:10.1017/S175173111800349X. PMID 31280745.
- Tatone EH, Gordon JL, Hubbs J, LeBlanc SJ, DeVries TJ, Duffield TF (2016). "A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests for the detection of hyperketonemia in dairy cows". Preventive Veterinary Medicine. 130: 18–32. doi:10.1016/j.prevetmed.2016.06.002. PMID 27435643.
- Pugh, D. G. 2002. Sheep and goat medicine. Saunders, Philadelphia. 468 pp.
- Kimberling, C. V. 1988. Jensen and Swift's diseases of sheep. 3rd Ed. Lea & Febiger, Philadelphia. 394 pp.
- Marteniuk JV, Herdt TH (1988). "Pregnancy toxemia and ketosis of ewes and does". The Veterinary Clinics of North America. Food Animal Practice. 4 (2): 307–15. doi:10.1016/s0749-0720(15)31050-1. PMID 3264753.
- Reid RL (1960). "Studies on the carbohydrate metabolism of sheep. IX. Metabolic effects of glucose and glycerol in undernourished pregnant ewes and in ewes with pregnancy toxaemia". Australian Journal of Agricultural Research. 11: 42–47. doi:10.1071/ar9600042.
- Van Soest, P. J. 1994. Nutritional ecology of the ruminant. 2nd Ed. Cornell Univ. Press. 476 pp.
- Kahn, C. M., ed. (2005). Merck Veterinary Manual (9th ed.). Whitehouse Station: Merck & Co.